Additionally, the anti-tumor efficacy of the anti-PD-L1 antibody was significantly improved by anlotinib through the enhanced accumulation of antibodies in tumor tissue and modulation of anti-tumor immunity. This evidence concerns the gene CD274 and neoplasm.